Cellebrite DI
CLBT

Cellebrite DI (CLBT) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
NeedhamMaintainedBuy$12.50 from $15.00Aug 14, 2026
DA DavidsonMaintainedBuy$15.00 from $22.00Aug 14, 2026
JP MorganMaintainedOverweight$16.00 from $20.00Aug 14, 2026
Lake StreetMaintainedBuy$15.00 from $21.00Aug 14, 2026
DA DavidsonMaintainedBuy$22.00 from $20.00Aug 6, 2026
DA DavidsonInitiated CoverageBuy$20.00May 27, 2026
NeedhamMaintainedBuy$15.00 from $18.00May 15, 2026
NeedhamMaintainedBuy$18.00 from $24.00Feb 12, 2026
NeedhamMaintainedBuy$24.00 from $22.00Nov 13, 2025
B of A SecuritiesMaintainedBuy$25.00 from $24.00Nov 13, 2025
Lake StreetMaintainedBuy$23.00 from $22.00Nov 13, 2025
JP MorganMaintainedOverweight$24.00 from $23.00Nov 13, 2025
JP MorganMaintainedOverweight$23.00 from $20.00Sep 24, 2025
Lake StreetMaintainedBuy$22.00 from $24.00Aug 15, 2025
NeedhamMaintainedBuy$18.00 from $24.00Aug 14, 2025
NeedhamMaintainedBuy$24.00Jun 6, 2025
NeedhamMaintainedBuy$24.00 from $28.00May 14, 2025
JP MorganMaintainedOverweight$25.00 from $29.00May 12, 2025
NeedhamMaintainedBuy$28.00Apr 2, 2025
NeedhamMaintainedBuy$28.00Mar 27, 2025

Frequently asked questions

  • What is the latest analyst rating on CLBT?

    On Aug 14, 2026, Needham maintained Cellebrite DI at Buy with a price target of $12.50.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.